Updates are available Correction dated 2025-10-09
Click to view Correction: https://doi.org/10.1186/s12859-025-06274-2
-
Authors
Kong, Garth L.
Nguyen, Thai T.
Rosales, Wesley K.
Panikar, Anjali D.
Cheney, John H. W.
Lusardi, Theresa A.
Yashar, William M.
Curtiss, Brittany M.
Carratt, Sarah A.
Braun, Theodore P.
Maxson, Julia E.
-
Funding
Funding for this research was provided by:
American Society of Hematology
National Cancer Institute
National Institutes of Health
- License Information
-
More Information
Article History
Received: 24 February 2023
Accepted: 26 March 2024
First Online: 2 April 2024
Change Date: 9 October 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12859-025-06274-2
Declarations
:
: Not applicable.
: Not applicable.
: JEM receives funding or collaborates with Blueprint Medicines, Kura Oncology and Ionis Pharmaceuticals. WMY is a former employee of Abreos Biosciences, Inc. and was compensated in part with common stock options. Pursuant to the merger and reorganization agreement between Abreos Biosciences, Inc. and Fimafeng, Inc., WMY surrendered all of his common stock options in 03/2021. TPB has received research support from AstraZeneca, Blueprint Medicines as well as Gilead Sciences and is the institutional PI on the FRIDA trial sponsored by Oryzon Genomics. The other authors declare that they have no competing interests.
